Who are L. reuteri Prodentis® lozenges's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Mixture of three Bifidobacteria, E. coli Nissle suspension, Combizym + Bifidobacteri, Lactobacillus Fermentum, Synbiotic 2000, Clotrimazole vaginal tablets+ Lactobacillus.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/l-reuteri-prodentis-lozenges.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

L. reuteri Prodentis® lozenges — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

L. reuteri Prodentis® lozenges (L. reuteri Prodentis® lozenges) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Probiotic. Area: Dentistry / Oral Health.

marketed Probiotic Dentistry / Oral Health Small molecule Live · refreshed every 30 min

Target snapshot

L. reuteri Prodentis® lozenges (L. reuteri Prodentis® lozenges) — University of Zagreb. L. reuteri Prodentis® is a probiotic lozenge containing Lactobacillus reuteri that colonizes the oral cavity and modulates the local oral microbiome to reduce pathogenic bacteria and promote gum health.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
L. reuteri Prodentis® lozenges TARGET	L. reuteri Prodentis® lozenges	University of Zagreb	marketed	Probiotic
Mixture of three Bifidobacteria	Mixture of three Bifidobacteria	Federico II University	marketed	Probiotic
E. coli Nissle suspension	E. coli Nissle suspension	University of Hohenheim	marketed	Live biotherapeutic product (probiotic)
Combizym + Bifidobacteri	Combizym + Bifidobacteri	RenJi Hospital	marketed	Enzyme and probiotic combination
Lactobacillus Fermentum	Lactobacillus Fermentum	HEM Pharma Inc.	marketed	Live biotherapeutic / Probiotic
Synbiotic 2000	Synbiotic 2000	Beth Israel Medical Center	marketed	Synbiotic (prebiotic + probiotic combination)
Clotrimazole vaginal tablets+ Lactobacillus	Clotrimazole vaginal tablets+ Lactobacillus	Peking University Shenzhen Hospital	marketed	Antifungal + probiotic combination	Fungal lanosterol 14α-demethylase (CYP51); Lactobacillus competitive exclusion and microbiota restoration

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Probiotic class)

BioBalance Corporation · 1 drug in this class
Biocodex · 1 drug in this class
CD Pharma India Pvt. Ltd. · 1 drug in this class
CHU de Quebec-Universite Laval · 1 drug in this class
Chuncheon Sacred Heart Hospital · 1 drug in this class
Dow University of Health Sciences · 1 drug in this class
Federico II University · 1 drug in this class
Fundación Hospital de Pediatría Prof. Dr. Juan P. Garrahan · 1 drug in this class
GWT-TUD GmbH · 1 drug in this class
Aga Khan University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). L. reuteri Prodentis® lozenges — Competitive Intelligence Brief. https://druglandscape.com/ci/l-reuteri-prodentis-lozenges. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab